NCT00632385 - Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy | Biotech Hunter

Enrollment

127

Participants

Timeline

Start Date

January 31, 2003

Study Completion Date

August 31, 2003

Conditions

Migraine

Interventions

DRUG

Eletriptan

40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred \>2 hours from first dose and within 24 hours of first dose

Trial Locations (16)

22304

Pfizer Investigational Site, Alexandria

27403

Pfizer Investigational Site, Greensboro

30067

Pfizer Investigational Site, Marietta

33324

Pfizer Investigational Site, Plantation

33609

Pfizer Investigational Site, Tampa

33710

Pfizer Investigational Site, St. Petersburg

45219

Pfizer Investigational Site, Cincinnati

46601

Pfizer Investigational Site, South Bend

63017

Pfizer Investigational Site, Chesterfield

65804

Pfizer Investigational Site, Springfield

78229

Pfizer Investigational Site, San Antonio

92618

Pfizer Investigational Site, Irvine

94109

Pfizer Investigational Site, San Francisco

97401

Pfizer Investigational Site, Eugene

92660-2452

Pfizer Investigational Site, Newport Beach

01757

Pfizer Investigational Site, Milford

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY